The FDA has confirmed it is conducting its own study to assess the risk of NAION—Non-Arteritic Anterior Ischemic Optic Neuropathy—associated with GLP-1 drugs including Ozempic. The disclosure, first reported by NPR on October 10, 2026, marks a notable step for an agency that has so far stopped short of requesting warning-label changes despite receiving reports of serious eye-harm cases.
NAION is a condition involving optic nerve damage that can lead to sudden vision loss, and in some cases the harm may be permanent. The FDA’s decision to launch an independent safety study suggests the agency considers the emerging signal credible enough to warrant its own evaluation, separate from the patient and physician reports already surfacing.
The development carries significant implications for the multi-billion-dollar GLP-1 drug class, which includes widely prescribed medications such as semaglutide and tirzepatide. Prescribing guidance, informed-consent practices, and future labeling could all be affected depending on what the FDA’s study finds.
What happened
According to NPR, the FDA confirmed via email that it is actively evaluating claims linking GLP-1 drugs to NAION. The agency stated that while it has received reports of serious eye-harm cases, it has not yet requested any changes to warning labels for GLP-1 medications.
The FDA’s confirmation that it is running its own study—rather than relying solely on adverse-event reports or manufacturer-conducted analyses—signals a proactive regulatory posture. The agency appears to be treating the NAION signal as significant enough to justify independent investigation before deciding whether regulatory action is warranted.
Why it matters
NAION is a serious and potentially permanent adverse event. Sudden vision loss from optic nerve damage can have life-altering consequences for patients.
The FDA’s independent study matters for several reasons:
- Prescribers and patients: If the FDA’s study confirms an association, physicians may need to update informed-consent discussions and screening practices before initiating GLP-1 therapy.
- Telehealth platforms: Companies prescribing GLP-1 medications remotely could face new requirements to disclose NAION risks as part of their intake and consent processes.
- Compounding pharmacies: Pharmacies dispensing compounded GLP-1 formulations may need to revisit labeling and patient counseling materials depending on regulatory outcomes.
- Drugmakers and investors: Eli Lilly, Novo Nordisk, and Amgen all have significant exposure to the GLP-1 market. Any labeling change or boxed warning could affect prescribing patterns and commercial performance.
It is important to note that the FDA has not concluded that GLP-1 drugs cause NAION. The agency has not requested label changes, issued a safety communication, or taken formal regulatory action. The study is ongoing, and its findings have not yet been published.
What to watch next
- Publication or public summary of the FDA’s NAION study results, including methodology and conclusions.
- Any FDA decision on whether to request warning-label updates or issue a formal drug safety communication for GLP-1 medications.
- Potential responses from GLP-1 manufacturers, including additional post-marketing studies or label revisions initiated voluntarily.
- Developments in litigation involving patients alleging NAION-related vision loss tied to GLP-1 use.
- Whether telehealth prescribers and compounding pharmacies begin updating risk-disclosure materials in anticipation of possible regulatory action.
Sources
NPR — FDA conducting its own study to assess NAION risks with GLP-1 drugs
Industry information only. Not medical or legal advice.
